Pulsenmore Ltd. Ordinary Shares

Pulsenmore Ltd. Ordinary Shares

PLSM
Pulsenmore Ltd. Ordinary SharesUS flagNASDAQ Global Market
3.60
USD
+0.04
- -
23.41MMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
0.31
1.79
0.97
1.51
6.21
Basic EPS, GAAP
-0.83
-2.4
-4.96
-3.67
-9.15
-5.74
-2.46
Free Cash Flow per Basic Share
-0.67
-1.72
-5.19
-5.31
-8.37
-6.55
-5.12
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.83
-4.23
-9.65
-11.93
-20.39
-26.12
-28.43
Tangible Book Value per Share
0.65
0.5
29.76
31.08
20.65
15.13
12.9
Basic Weighted Avg Shares
6
6
5
6
6
6
6
Sales/Revenue/Turnover
- -
- -
2
11
6
10
40
Operating Margin (%)
- -
- -
-1,390.62
-427.24
-898.29
-436.96
-30.39
Depreciation Expense
- -
- -
1
1
2
3
3
Net Income, GAAP
-5
-14
-26
-22
-59
-37
-16
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-1,623.89
-204.54
-946.46
-380.25
-39.61
Working Capital
4
5
159
196
152
118
71
LT Debt
- -
- -
- -
3
2
1
1
Total Equity
4
3
154
188
132
97
83
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1,033.47%
-14.24%
Free Cash Flow
- -
43.19%
-21.35%
Net Income, GAAP
- -
28.7%
-56.85%
Sales/Revenue/Turnover
- -
- -
314.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
6
2024
- -
- -
- -
- -
10
2025
- -
- -
- -
- -
40

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-9.15
2024
- -
- -
- -
- -
-5.74
2025
- -
- -
- -
- -
-2.46

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Elazar Sonnenschein
Full Time Employees
63
Sector
Healthcare
Industry
Medical - Devices
Address
8 Omarim Street Omer HD Israel 8496500
IPO Date
Jan 21, 2026
Business
Pulsenmore Ltd. is an Israel-based medical technology company that develops, manufactures, and markets portable home ultrasound solutions for remote patient examination and telehealth-enabled monitoring, with products designed for obstetric and fertility-related applications. Headquartered in Israel, the company focuses on bringing ultrasound imaging into the home through compact devices, cloud-based image handling, and clinician-reviewed platforms. Main products and services - Pulsenmore ES: a handheld home ultrasound system designed for prenatal imaging and remote monitoring, including a compact ultrasound unit, cradle/docking, smartphone integration, and cloud-based image uploading for clinician review. - Pulsenmore FC: a self-test ultrasound platform for monitoring follicle size in women undergoing fertility treatments, comprising a miniaturized ultrasound device paired with patient-facing software and clinician oversight. - Telehealth-enabled imaging services: cloud storage, secure data transmission, clinician dashboards for remote interpretation, and telemedicine workflows that support remote diagnosis and monitoring. - Hardware and software integration: portable ultrasound hardware with smartphone/app interfaces and cloud-based data management to enable remote follow-up and documentation. Latest major company changes - Strategic expansion into home-use ultrasound markets with ongoing commercialization of Pulsenmore ES in multiple regions; continues to advance regulatory approvals and market deployments. - Initiation or expansion of collaboration efforts to integrate telehealth capabilities with existing healthcare systems, reflecting a broader push into remote diagnostic workflows. - Ongoing commercial activity around Pulsenmore FC, targeting fertility clinics and patients in Israel with continued product refinement and regulatory updates to support broader adoption. Industry context and markets - Industry: medical devices, focused on point-of-care and home-based imaging technologies; telehealth-enabled diagnostic solutions. - Business segments: home ultrasound devices for obstetrics and fertility monitoring; related software as a service for data management and clinician review; telehealth integrations. - Target markets: healthcare providers, fertility clinics, obstetric care settings, and patients seeking remote diagnostic options; global deployment with emphasis on Israel and other international markets. - Geographic operations: headquarters in Israel; products marketed and sold worldwide, with regulatory considerations in multiple jurisdictions. Founding information and corporate relationships - Founding year: 2014. - Headquarters: Israel. - Corporate relationships: operates as an independent medical device company; engages in partnerships and collaborations to expand telehealth-enabled imaging solutions (exact parent/sibling structures are not specified in the provided data).

Company News

APIChatGPT
  • Pulsenmore Selected for Israel Innovation Authority and Ministry of Health Program to Lead an $1 Million AI Development Project

  • Pulsenmore Announces Pricing of $7.5 Million Private Placement with a Single Healthcare Focused Institutional Investor

  • Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States

  • Pulsenmore Announces Full Year 2025 Financial Results and Webcast

  • Pulsenmore Announces Full Year 2025 Earnings Conference Call

  • Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance

  • Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center

  • Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation

  • Pulsenmore To Commence Trading on Nasdaq as It Expands FDA-authorized Home Prenatal Ultrasound Devices in the U.S.